US 12,410,397 B2
Methods of enhancing cell survival of stem cells
Yue Xu, San Diego, CA (US); and Sheng Ding, La Jolla, CA (US)
Assigned to The Scripps Research Institute, La Jolla, CA (US)
Filed by The Scripps Research Institute, La Jolla, CA (US)
Filed on Mar. 8, 2021, as Appl. No. 17/195,385.
Application 15/098,546 is a division of application No. 14/188,616, filed on Feb. 24, 2014, granted, now 9,340,525, issued on May 17, 2016.
Application 14/188,616 is a division of application No. 13/132,379, granted, now 8,691,573, issued on Apr. 8, 2014, previously published as PCT/US2009/066554, filed on Dec. 3, 2009.
Application 17/195,385 is a continuation of application No. 16/431,643, filed on Jun. 4, 2019, granted, now 10,975,352.
Application 16/431,643 is a continuation of application No. 15/863,501, filed on Jan. 5, 2018, granted, now 10,351,822, issued on Jul. 16, 2019.
Application 15/863,501 is a continuation of application No. 15/098,546, filed on Apr. 14, 2016, granted, now 9,896,655, issued on Feb. 2, 2018.
Claims priority of provisional application 61/200,808, filed on Dec. 3, 2008.
Prior Publication US 2021/0403862 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/48 (2006.01); C07D 277/56 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C12N 5/0735 (2010.01)
CPC C12N 5/0606 (2013.01) [C07D 239/48 (2013.01); C07D 277/56 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C12N 2501/999 (2013.01)] 7 Claims
 
1. A composition comprising a compound of formula (II):

OG Complex Work Unit Chemistry
wherein,
L2 is substituted or unsubstituted C1-C10 alkylene;
y is an integer from 0 to 3;
z is an integer from 0 to 5;
X is —N═, —CH═ or —CR5═;
R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3, R4 and R5 are independently —CN, —S(O)nR6, —NR7R8, —C(O)R9, —NR10—C(O)R11, —NR12—C(O)—OR13, —C(O)NR14R15, —NR16S(O)2R17, —OR18, —S(O)2N(R19)2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, wherein n is an integer from 0 to 2, wherein if z is greater than 1, two R3 moieties are optionally joined together to form an substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18 and R19 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
or a racemate, diastereomer, tautomer, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof.